Abstract | OBJECTIVE: DESIGN: PubMed (including MEDLINE), EMBASE and CENTRAL were searched up to October 26, 2009 for randomized placebo controlled trials (RCTs) on neuropathic pain. The methodological quality of the included trials was independently assessed by two authors using the Delphi list. Fixed or random effects model were used to calculate the summary effect size using Hedges' g. SETTING: NA. PATIENTS: INTERVENTIONS: OUTCOME MEASUREMENTS: The outcome of measurements was the reduction of spontaneous pain. RESULTS: Twenty-eight studies were included, meeting the inclusion criteria. Summary effect sizes were calculated for subgroups of studies evaluating ketamine IV in complex regional pain syndrome (CRPS), oral memantine in postherptic neuralgia and, respectively, ketamine IV, and oral memantine in postamputation pain. Treatment with ketamine significantly reduced pain in postamputation pain (pooled summary effect size: -1.18 [confidence interval (CI) 95% -1.98, -0.37], P = 0.004). No significant effect on pain reduction could be established for ketamine IV in CRPS (-0.65 [CI 95% -1.47, 0.16], P = 0.11) oral memantine in postherptic neuralgia (0.03 [CI 95% -0.51, 0.56], P = 0.92) and for oral memantine in postamputation pain (0.38 [CI 95% -0.21, 0.98], P = 0.21). CONCLUSIONS:
|
Authors | Susan Collins, Marnix J Sigtermans, Albert Dahan, Wouter W A Zuurmond, Roberto S G M Perez |
Journal | Pain medicine (Malden, Mass.)
(Pain Med)
Vol. 11
Issue 11
Pg. 1726-42
(Nov 2010)
ISSN: 1526-4637 [Electronic] England |
PMID | 21044263
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review, Systematic Review)
|
Copyright | Wiley Periodicals, Inc. |
Chemical References |
- Excitatory Amino Acid Antagonists
- Receptors, N-Methyl-D-Aspartate
- Ketamine
- Memantine
|
Topics |
- Excitatory Amino Acid Antagonists
(therapeutic use)
- Humans
- Ketamine
(therapeutic use)
- Memantine
(therapeutic use)
- Neuralgia
(drug therapy)
- Randomized Controlled Trials as Topic
- Receptors, N-Methyl-D-Aspartate
(antagonists & inhibitors)
|